Novo Nordisk is exploring flexible pricing options with healthcare systems, to improve the distribution of Wegovy to obese patients.
Julius Bär has a €606m exposure to a “European conglomerate” that everyone understands to be Signa.
Uniper has to pay €550m to a European supplier o…
© MarketScreener.com 2023
Julius Bär has a €606m exposure to a “European conglomerate” that everyone understands to be Signa.
Uniper has to pay €550m to a European supplier o…
© MarketScreener.com 2023